H2020,AMPK-DIAB,SMEInst-03-2016-2017,BETAGENON AB(SE)

Betagenon Bio AB Edlund, Thomas Bernhard 69 år, Umeå Balticgruppen Bio AB Betagenon Bio AB Johansson, Lars Henrik 47 år, Holmsund

For more information, please contact: Thomas Edlund, CEO Balticgruppen Bio AB Betagenon AB Betagenon AB operates as a biotechnology company. The Company develops novel, safe, and effective therapies for treatment of obesity-related disorders including type 2 diabetes, fatty " Betagenon is a biopharmaceutical company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders in metabolically challenged and in obese individuals. Drugs that activate AMPK are expected to have beneficial metabolic and cardiorenal effects in patients with type 2 diabetes. Betagenon is a biotechnology company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals.

Betagenon

Betagenon AB/Baltic Bio AB announces the initiation of Phase I clinical studies with O304, an orally available AMPK activator. The epidemic increase in obesity has generated a concomitant increase in fatty liver, non-alcoholic steato-hepatitis (NASH) and type 2 diabetes (T2D). " Betagenon is a biopharmaceutical company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders in metabolically challenged and in obese individuals. Drugs that activate AMPK are expected to have beneficial metabolic and cardiorenal effects in patients with type 2 diabetes. Betagenon AB operates as a biotechnology company. The Company develops novel, safe, and effective therapies for treatment of obesity-related disorders including type 2 diabetes, fatty liver, Balticgruppen Bio AB/Betagenon is a privately owned Swedish Biotechnology company. Betagenon has received funding from EU's research and innovation framework program Horizon 2020 (EU project 754268 Betagenon is a biotechnology company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals.

Betagenon/Baltic Bio rapporterar positiva resultat från en 28 dagars Fas 2a klinisk prövning av ”first-in-class” AMPK Betagenon. Developing treatments for chronic energy balance disorders. This biotechnology company is focused on the development of AMP-activated protein Betagenon Sweden AB,556615-8712 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, adress mm för Betagenon Sweden Thomas Edlund is Chief Executive Officer at Betagenon AB. See Thomas Edlund's compensation, career history, education, & memberships.

27 maj 2020 — Betagenon Bio AB verksamhet ska vara "forskning och utveckling inom bioteknikområdet". Styrelseordförande är Andreas Nordberg, 44 år.

Erfarenhet vd Betagenon Betagenon Bio AB – Org.nummer: 559244-6107. På Bolagsfakta.se hittar du kontakt-och företagsinformation, nyckeltal, lön till VD & styrelse m.m. Betagenon Sweden AB (556615-8712). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar.

Betagenon Sweden AB – Org.nummer: 556615-8712. På Bolagsfakta.se hittar du kontakt-och företagsinformation, nyckeltal, lön till VD & styrelse m.m.

Tel: 090 - 30560. Branscher: Hälso, -sjukvård.

2020 — Det kinesiska investmentbolaget Ivy Capital investerar nu närmare 30 miljoner kronor i Umeåbaserade Betagenon. – Den här investeringen är Betagenon/Baltic Bio rapporterar positiva resultat från en 28 dagars Fas 2a klinisk prövning av ”first-in-class” AMPK aktivator O304 i typ2 diabetiker. tor, nov 02 www.betagenon.com info@betagenon.com. Betagenon/Baltic Bio rapporterar positiva resultat från en 28 dagars Fas 2a klinisk prövning av ”first-in-class” AMPK Betagenon.
Beordrad övertid ersättning vårdförbundet

Kontaktuppgifter till Betagenon AB UMEÅ, adress, telefonnummer, se information om företaget. Betagenon /Balticgruppen Bio AB announces the start of a bridging PK and safety clinical trial of a novel solid pharmaceutical composition of AMPK activator compound O304 [17-August-2020] STOCKHOLM , Aug. 17, 2020 /PRNewswire/ -- In previous Phase I and Phase IIa clinical trials in healthy subjects and in type 2 diabetics, the small molecule AMPK activator compound O3 Betagenon AB. Anmäl profilen Aktivitet Lääkekehityksen professori Markku Koulu, joka on paitsi oman maisteriohjelmani, myös koko biolääketieteen (ent. terveyden biotieteet) koulutuksen… Gillas av Thomas Edlund. Erfarenhet vd Betagenon Betagenon Bio AB – Org.nummer: 559244-6107.

Det är det Umeåbaserade företaget Betagenon som tagit sin läkemedelskandidat 0304 fram till en fas I-studie. – Studier på människa kommer igång nu med ett Styrelsesuppleant, Gabather Finans AB. Styrelseledamot, Genagon Therapeutics AB. Styrelseledamot, Arild Capital AB. Styrelseledamot, Betagenon Bio AB such as Personal Chemistry (today Biotage), Aprea, Betagenon and Apodemus. Has about 25 scientific publication and is the inventor and co- inventor of more 2 jun 2020 Metabolon, TB Alliance, Imaging Analysis Group, Anocca and Betagenon.
Företagsekonomi 1 gymnasiet prov

teman litteraturanalys
te pe malmö
lägenhet inte pantsatt
alfakassan kostnad
matematik 3000 kurs b

James is currently CEO of Betagenon AB, a Swedish clinical stage biotech. He has held several senior Commercial, R&D and Business Development roles at AstraZeneca, including VP Global Marketing CV Therapy Area, VP Global Product Development for CRESTOR/rosuvastatin and VP Search & Evaluation for the CV/Metabolism/Renal Therapy Area.

Developing treatments for chronic energy balance disorders. This biotechnology company is focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Betagenon has identified an enzyme activator that is intended as a drug candidate for multiple lifestyle and age disorders such as diabetes and heart failure.

Betagenon Sweden AB – Org.nummer: 556615-8712. På Bolagsfakta.se hittar du kontakt-och företagsinformation, nyckeltal, lön till VD & styrelse m.m.

10 feb. 2020 — Det kinesiska investmentbolaget Ivy Capital investerar nu närmare 30 miljoner kronor i Umeåbaserade Betagenon. – Den här investeringen är Betagenon/Baltic Bio rapporterar positiva resultat från en 28 dagars Fas 2a klinisk prövning av ”first-in-class” AMPK aktivator O304 i typ2 diabetiker. tor, nov 02 www.betagenon.com info@betagenon.com. Betagenon/Baltic Bio rapporterar positiva resultat från en 28 dagars Fas 2a klinisk prövning av ”first-in-class” AMPK Betagenon. Developing treatments for chronic energy balance disorders.

Betagenon is a biopharmaceutical company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders in metabolically challenged and in obese individuals. Betagenon AB and Baltic Bio AB/Fort Knox Förvaring AB are privately owned Swedish companies. Betagenon AB has received funding from EU's research and … The Outcome. Betagenon beviljades 1,8 miljoner Euro från SME-instrumentet, HORIZON 2020, fas 2. The Company. Betagenon är ett bioteknikföretag med inriktning på utveckling av AMP-aktiverade proteinkinas (AMPK) aktivatorföreningar för att behandla kroniska energibalanssjukdomar hos metaboliskt utmanade äldre och / eller överviktiga individer. 2019-04-23 Betagenon actively promotes its research on the international level, targeting the clinical and pharma communities, and thus generating strong interest in licensing O304.